Alliance Global Partners Initiates Coverage On Lipocine with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk 2 years ago
NewsPrice TargetInitiationAnalyst Ratings
Alliance Global Partners analyst Scott Henry initiates coverage on Lipocine (NASDAQ:LPCN) with a Buy rating and announces Price Target of $10.
Alliance Global Partners analyst Scott Henry initiates coverage on Lipocine (NASDAQ:LPCN) with a Buy rating and announces Price Target of $10.